Drugs / HRS-9231
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06519981 | Aug → Sep 2024 | MRI defined brain infarct | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06657560 | Oct 2024 → Jul 2025 | MRI defined brain infarct | Shanghai Shengdi Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07123376 | Jun → Oct 2024 | — | Shanghai Shengdi Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06731829 | Dec 2024 → Apr 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07275814 | Nov 2025 → Jun 2026 | — | Shanghai Shengdi Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT07275723 | Nov 2025 → Apr 2026 | — | Shanghai Shengdi Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275723 ↗ |
| Modality | Diagnostic / imaging agent | “HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)” NCT07275814 ↗ |
| Route | Intravenous | “administered through IV injection” NCT06519981 ↗ |